

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on March 31 2009

TOWNSEND and TOWNSEND and CREW LLP

By: *[Signature]*

**AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1633**

PATENT

Attorney Docket No.: 082368-001500US
Client Ref. No.: E1-A0305Y1P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ITO and SAITO

Application No.: 10/518,472

Filed: October 4, 2005

For: PRIMARY CULTURED
ADIPOCYTES FOR GENE THERAPY

Customer No.: 20350

Confirmation No. 8056

Examiner: Sajjadi, Fereydoun Ghotb

Technology Center/Art Unit: 1633

**AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1633**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

In response to the Final Office Action mailed October 2, 2008 on the above-referenced application, please enter the following amendments and remarks. This amendment is accompanied by a Declaration under 37 C.F.R. § 1.132, a Request for Continued Examination (RCE) and a three-month Request for Extension of Time, extending the time for responding until April 2, 2009.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.